H.C. Wainwright raised the firm’s price target on Caribou Biosciences (CRBU) to $9 from $3 and keeps a Buy rating on the shares. The firm cites the new data for vispa-cel and CB-011 for the target increase.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBU:
- 3 Penny Stocks to Watch Now, 11/4/25
- Caribou Biosciences price target raised to $8 from $5 at Citi
- Caribou Biosciences Reports Positive ANTLER Phase 1 Results
- Caribou Biosciences announces results from CaMMouflage Phase 1 trial
- Caribou Biosciences announces results from ANTLER phase 1 trial of vispa-cel